A clinical predictive model based on data in a cohort of 315 advanced melanoma with pembrolizumab or nivolumab suggests age <65 years and female sex as independent risk factors to the lower immune response to anti-PD-1 treatment.203 Consistent with the foregoing, another analysis based on a cohort of 538 patients suggests aged> 60 years respond to more efficient anti-PD-1. Here, PDCD1 is linked to melanoma.